Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital

EQS-Ad-hoc: Heidelberg Pharma AG / Key word(s): Significant contracts Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital 07-March-2026 / 02:03 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group. The issuer is solely responsible for the content of this announcement. Ad hoc announcement - Disclosure of inside information under Article 17 of Regulation (EU) No 596/2014

Heidelberg Pharma and HealthCare Royalty Announce Amendment to Existing Royalty Agreement and the Participation of Soleus Capital

• Heidelberg Pharma is eligible to receive USD 20 million upfront funded by Soleus Capital, subject to closing conditions
• USD 25 million to be funded by Soleus Capital upon FDA approval of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px; HCRx payment upon approval still in place

Ladenburg, Germany, 7 March 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced an additional amendment to its existing royalty purchase agreement with HealthCare Royalty (HCRx) and the participation of Soleus Capital Management, L.P. (Soleus Capital), a US-based life sciences investment firm, on behalf of its Soleus Capital Credit Opportunities Fund I, L.P. (and its affiliated funds). The amended agreement covers the partial monetization of Heidelberg Pharma’s future royalties on the worldwide sales of Telix Pharmaceuticals’ imaging diagnostic agent TLX250-Px. In conjunction with the amendment, Heidelberg Pharma is eligible to receive USD 20 million from Soleus Capital, subject to customary closing conditions. Another payment of USD 25 million will become due upon FDA approval of TLX250-Px.

In March 2024, Heidelberg Pharma entered into an agreement with HCRx for the sale of royalties on TLX250-Px up to a defined cap, which agreement was subsequently amended in March 2025. As part of the current amendment, Heidelberg has agreed to an increased cap on total payments alongside certain other contractual changes. The participation of Soleus Capital has no impact on the payments from HCRx.